Business Wire

H.I.G.-CAPITAL

Share
H.I.G. Capital Sells WERU Group to DOVISTA A/S

H.I.G. Capital (“H.I.G.“), a leading global alternative investment firm with over €36 billion of equity capital under management, is pleased to announce that an affiliate has signed a definitive agreement to sell its German portfolio company WERU Group (the “Company” or “WERU”) to DOVISTA A/S, a leading North European solution provider of vertical windows and exterior doors. The transaction is subject to clearance by the relevant antitrust authorities.

WERU, a leading manufacturer of PVC windows and doors in Germany, was acquired by H.I.G. in 2014, and subsequently acquired UNILUX, a leading manufacturer of wood-based windows and doors to expand its product portfolio. During H.I.G.’s ownership, WERU modernized the Company’s production facilities, launched new products, and implemented various digital innovations. Headquartered near Stuttgart in Germany, WERU sells its product offering via a broad network of more than 1,725 specialized retailers and has more than 1,100 employees across its three manufacturing sites in Germany.

Stefan Löbich, CEO of WERU, commented: “Over the past years, we worked very closely with H.I.G. and successfully implemented our jointly defined strategy. As a result, WERU is a major player within windows and doors in Germany today. Having an experienced, reliable, and financially strong partner such as H.I.G. on our side was extremely beneficial for the Company, and I thank H.I.G. for their continued support. Now I am truly excited to open a new chapter for WERU as part of DOVISTA Group.”

Allan Lindhard Jørgensen, CEO & President of DOVISTA A/S said: “Our two companies make a great fit. With the acquisition of WERU, we accelerate our plans to expand further and truly make all of Europe our home market. We add a notable German vertical windows and exterior doors brand to our existing brand portfolio and gain further traction in Germany which is a significant market for building a strong presence in Central Europe. We are delighted to welcome WERU and its employees to the DOVISTA family, and I very much look forward to working with the WERU team.”

Klaas Reineke, Managing Director at H.I.G., commented: “Working with Stefan Löbich and his team at WERU was a great pleasure for us. We worked closely with WERU management over the past years – with selected add-on acquisitions, continuous digitization efforts, and an even stronger customer focus, and as a result, WERU was able to strengthen its market position in Germany over the last years. We are convinced that WERU is very well positioned for further growth as part of DOVISTA, and we wish Stefan Löbich and his team every success for the future.”

About WERU

WERU is a leading German manufacturer of high-quality windows and external doors of residential buildings with a full range of frame materials and is headquartered in Rudersberg, Baden-Württemberg. WERU offers premium- and luxury products and WERU is perceived as a quality leader in the market. Among its competitors, WERU provides outstanding service quality, lead time, delivery reliability, and after sales support for specialist retailers. WERU has a renowned and distinguished brand, a "Made-in-Germany" reputation and a clear USP. WERU was awarded with "Deutsche Standards - Marke des Jahrhunderts" in 2019.

About DOVISTA

DOVISTA is a leading solution provider of vertical windows and exterior doors made from wood and wood/aluminium on the North European market. DOVISTA was founded in 2004 and is headquartered in Horsens, Denmark and today, more than 4,000 employees manufacture and distribute vertical windows and exterior doors to the core markets: Denmark, Sweden, Norway, the UK, and Ireland.

DOVISTA consists of nine distinctive brands with strong local roots that together represent about 600 years of experience within manufacturing of vertical windows and exterior doors: VELFAC, Rationel, SP Fönster, Traryd Fönster, Mockfjärds, O H Industri, Natre, Lian, and KRONE.

Every DOVISTA brand has its own market strategies, firmly anchored in its local markets, and closely connected to its customers. The brands also collaborate to create knowledge and synergies between the brands and strengthen the shared competences and qualities of the DOVISTA Group.

DOVISTA is part of the VKR Group and thereby, a sister company to VELUX. The VKR Group is owned by VKR Holding A/S, a limited company with a non-profit, charitable foundation as largest shareholder.

For more information, please refer to the DOVISTA website at www.DOVISTA.com .

About H.I.G. Capital

H.I.G. is a leading global alternative assets investment firm with over €36 billion of equity capital under management.* Based in Miami, and with offices in New York, Boston, Chicago, Dallas, Los Angeles, San Francisco, and Atlanta in the U.S., as well as international affiliate offices in London, Hamburg, Madrid, Milan, Paris, Bogotá, Rio de Janeiro and São Paulo, H.I.G. specializes in providing both debt and equity capital to small and mid-sized companies, utilizing a flexible and operationally focused/value-added approach:

1. H.I.G.’s equity funds invest in management buyouts, recapitalizations and corporate carve-outs of both profitable as well as underperforming manufacturing and service businesses.

2. H.I.G.’s debt funds invest in senior, unitranche and junior debt financing to companies across the size spectrum, both on a primary (direct origination) basis, as well as in the secondary markets. H.I.G. is also a leading CLO manager, through its WhiteHorse family of vehicles, and manages a publicly traded BDC, WhiteHorse Finance.

3. H.I.G.’s real estate funds invest in value-added properties, which can benefit from improved asset management practices.

Since its founding in 1993, H.I.G. has invested in and managed more than 300 companies worldwide. The firm's current portfolio includes more than 100 companies with combined sales in excess of €27 billion. For more information, please refer to the H.I.G. website at www.higcapital.com .

* Based on total capital commitments managed by H.I.G. Capital and affiliates.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

NHOA Energy Achieves Great Place To Work Certification in Italy, the United States and Australia18.12.2025 10:53:00 CET | Press release

NHOA Energy, global provider of utility-scale energy storage systems, announces that it has been certified Great Place To Work® in Italy, the United States, and Australia. The certification is based entirely on direct feedback from NHOA Energy employees, gathered through an independent and structured listening process. Great Place To Work® Certification™ assesses the quality of the employee experience across key dimensions such as credibility, respect, fairness, pride, and camaraderie. The results achieved by NHOA Energy reflect a corporate culture built on trust, inclusion, and the consistent commitment to valuing people within a dynamic and international environment. Employees highlighted particularly high levels of appreciation for the ethical and transparent behavior of leaders, the welcoming and inclusive approach toward new hires, and fair treatment across diversity, equity, and inclusion dimensions. A strong majority also expressed pride in working at NHOA Energy and reported a

Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 10:00:00 CET | Press release

The deal further strengthens Regnology’s global position in Regulatory Reporting and significantly accelerates its expansion into new markets Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeki

Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 10:00:00 CET | Press release

Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ

Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press release

Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants treated with zasocitinib achieved clear or almost clear skin (PASI 90), and on average about 30 percent achieved completely clear skin (PASI 100) by week 16 Zasocitinib was generally well-tolerated with a safety profile consistent with previous clinical studies Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at wee

DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 08:30:00 CET | Press release

Based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s DATROWAY is the first and only medicine to significantly improve overall survival versus chemotherapy in this patient population If approved, DATROWAY could become the standard of care in this setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Produc

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye